Home>>Signaling Pathways>> Metabolism>> Phosphodiesterase>>3,3'-((2-Chlorophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one)

3,3'-((2-Chlorophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one)

Catalog No.GC46030

An ENPP1 inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

3,3'-((2-Chlorophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) Chemical Structure

Cas No.: 4322-58-1

Size Price Stock Qty
1mg
$49.00
In stock
5mg
$199.00
In stock
10mg
$374.00
In stock
25mg
$870.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

3,3'-((2-Chlorophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) is a non-nucleotide inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1; Ki = 50 μM).1,2 It also inhibits urease (IC50 = 84.53 μM for the Jack bean enzyme).3

|1. Choudhary, M.I., Fatima, N., Khan, K.M., et al. New biscoumarin derivatives-cytotoxicity and enzyme inhibitory activities. Bioorg. Med. Chem. 14(23), 8066-8072 (2006).|2. Onyedibe, K.I., Wang, M., and Sintim, H.O. ENPP1, an old enzyme with new functions, and small molecule inhibitors - A STING in the tale of ENPP1. Molecules 24(22), E4192 (2019).|3. Khan, K.M., Iqbal, S., Lodhi, M.A., et al. Biscoumarin: New class of urease inhibitors; economical synthesis and activity. Bioorg. Med. Chem. 12(8), 1963-1968 (2004).

Reviews

Review for 3,3'-((2-Chlorophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one)

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 3,3'-((2-Chlorophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.